Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2024;35(1):134-42
Article Links
A Study on the Immunoregulatory Role of the PD1 Pathway in Juvenile Idiopathic Arthritis
Artemis Koutsonikoli, Anna Taparkou, Polyxeni Pratsidou-Gertsi, Vasiliki Sgouropoulou, Maria Trachana
Authors Information

First Department of Paediatrics, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

A Koutsonikoli, A Taparkou, P Pratsidou-Gertsi, V Sgouropoulou, M Trachana

Keywords: PD1 pathway, JIA, immune checkpoint, biomarkers
References
  1. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine 2014;81:112-7.
  2. Espinosa M, Gottlieb BS. Juvenile idiopathic arthritis. Pediatr Rev 2012;33:303-13.
  3. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015;74:1854-60.
  4. Nalbanti P, Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Farmaki E, Bamidis P, et al. Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment. Rheumatol Int 2018;38:1241-50.
  5. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
  6. Koutsonikoli Α, Trachana Μ, Pardalos G, Pratsidou-Gertsi P, Kanakoudi-Tsakalidou F. Time-interval between onset of symptoms and diagnosis of Juvenile Idiopathic Arthritis: Evaluation of 416 patients in two decades. Paediatriki of Northern Greece 2010;22:37-44.
  7. van Loosdregt J, van Wijk F, Prakken B, Vastert B. Update on research and clinical translation on specific clinical areas from biology to bedside: Unpacking the mysteries of juvenile idiopathic arthritis pathogenesis. Best Pract Res Clin Rheumatol 2017;31:460-75.
  8. Ceeraz S, Nowak EC, Burns CM, Noelle RJ. Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther 2014;16:469.
  9. Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F. News on immune checkpoint inhibitors as immunotherapy strategies in adult and paediatric solid tumors. Semin Cancer Biol 2022;79:18-43.
  10. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
  11. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
  12. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance; Paediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929-36.
  13. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658-66.
  14. Cai L, Zhang C, Wu J, Zhou W, Chen T. Decreased PD-1 expression on circulating CD4+T cell and PD-L1 expression on myeloid dendritic cell correlate with clinical manifestations in systemic juvenile idiopathic arthritis. Joint Bone Spine 2019;86:61-8.
  15. Shenoi S, Ou JN, Ni C, Macaubas C, Gersuk VH, Wallace CA, et al. Comparison of biomarkers for systemic juvenile idiopathic arthritis. Pediatr Res 2015;78:554-9.
  16. Luo Q, Ye J, Zeng L, Luo Z, Deng Z, Li X, et al. Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis. Mol Med Rep 2018;17:3297-305.
  17. Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature 2017;542:110-4.
  18. Li S, Liao W, Chen M, Shan S, Song Y, Zhang S, et al. Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis. Inflammation 2014;37:116-21.
  19. de Roock S, Keustermans G, Duurland CL, Wehrens EJM, van Wijk F, Prakken BJ. PD-1/PD-L1 signaling in JIA synovial regulatory T cell function. [abstract] Pediatr Rheumatol Online J 2011;9(Suppl 1):P279.
  20. Petrelli A, Mijnheer G, Hoytema van Konijnenburg DP, van der Wal MM, Giovannone B, Mocholi E, et al. PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation. J Clin Invest 2018;128:4669-81.
  21. Maschmeyer P, Heinz GA, Skopnik CM, Lutter L, Mazzoni A, Heinrich F, et al. Antigen-driven PD-1+ TOX+ BHLHE40+ and PD-1+ TOX+ EOMES+ T lymphocytes regulate juvenile idiopathic arthritis in situ. Eur J Immunol 2021;51:915-29.
  22. Hatachi S, Iwai Y, Kawano S, Morinobu S, Kobayashi M, Koshiba M, et al. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 2003;30:1410-9.
  23. Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006;177:8844-50.
  24. Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum 2010;62:1870-80.
  25. Moret FM, van der Wurff-Jacobs KM, Bijlsma JW, Lafeber FP, van Roon JA. Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions. Arthritis Res Ther 2014;16:497.
  26. Bommarito D, Hall C, Taams LS, Corrigall VM. Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol 2017;188:455-66.
  27. Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, et al. Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS One 2018;13:e0192704.
  28. Greisen SR, Rasmussen TK, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Hvid M, et al. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol 2014;43:101-8.
  29. Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis Res Ther 2015;17:340.
  30. Cai L, Zhang C, Wu J, Zhou W, Chen T. Unbalanced expression of membrane-bound and soluble programmed cell death 1 and programmed cell death ligand 1 in systemic juvenile idiopathic arthritis. Clin Immunol 2021;229:108800.
  31. Sag E, Demir S, Aspari M, Nielsen MA, Skejø C, Hvid M, et al. Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes. Pediatr Res 2021;90:744-51.